Main info

Identifier:

HOVON 135 AML

Sponsor:

HOVON

Working group party:

Leukemia

Age:

> 65

Stage:

1st Line

Echelon:

Level C-HIC&C-SCT

Included patients:

148

(of 140)

Active sites:

38

(of 39)

Title:

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI ≥ 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged ≥ 66 years.
A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients.

Timeline

Flow

Details

Phase:

Prospective randomized Phase II study

Monitoring Type:

Not any more

Objectives:

Participating Sites

= Active hospitals

= Inactive hospitals